Microtubule Binding and Disruption and Induction of Premature Senescence by Disorazole C<sub>1</sub> [S]


Received October 10, 2008; accepted December 8, 2008

ABSTRACT

Disorazoles comprise a family of 29 macrocyclic polyketides isolated from the fermentation broth of the myxobacterium Sorangium cellulosum. The major fermentation product, disorazole A<sub>1</sub>, was found previously to irreversibly bind to tubulin and to have potent cytotoxic activity against tumor cells, possibly because of its highly electrophilic epoxide moiety. To test this hypothesis, we synthesized the epoxide-free disorazole C<sub>1</sub> and found it retained potent antiproliferative activity against tumor cells, causing prominent G<sub>2</sub>/M phase arrest and inhibition of in vitro tubulin polymerization. Furthermore, disorazole C<sub>1</sub> produced disorganized microtubules at interphase, misaligned chromosomes during mitosis, apoptosis, and premature senescence in the surviving cell populations. Using a tubulin polymerization assay, we found disorazole C<sub>1</sub> inhibited purified bovine tubulin polymerization, with an IC<sub>50</sub> of 11.8 ± 0.4 μM, and inhibited [3H]vinblastine binding noncompetitively, with a K<sub>i</sub> of 4.5 ± 0.6 μM. We also found noncompetitive inhibition of [3H]dolastatin 10 binding by disorazole C<sub>1</sub>, with a K<sub>i</sub> of 10.6 ± 1.5 μM, indicating that disorazole C<sub>1</sub> bound tubulin uniquely among known antimitotic agents. Disorazole C<sub>1</sub> could be a valuable chemical probe for studying the process of mitotic spindle disruption and its relationship to premature senescence.

Natural products have provided a plethora of pharmaceutically useful drugs and chemical probes. The disorazole polyene macrodiolides were first isolated from the myxobacterium Sorangium cellulosum in 1994 and characterized to have significant antifungal activity with no antibacterial activity (Jansen et al., 1994). Initial biochemical and pharmacological studies were restricted to the major fermentation product, disorazole A<sub>1</sub> (Fig. 1), which blocks cell proliferation, causes G<sub>2</sub>/M phase arrest and loss of microtubules, and induces apoptosis. Moreover, it blocks in vitro polymerization of tubulin (Elnakady et al., 2004; Kopp et al., 2005). Disorazole A<sub>1</sub> contains a highly electrophilic divinyl oxirane moiety that we hypothesized might mediate the mitotic arrest and inhibition of tubulin polymerization through covalent binding to tubulin (Wipf et al., 2006). The highly electrophilic divinyl oxirane of disorazole A<sub>1</sub> is generally not viewed as a therapeutically desirable moiety; therefore, we synthesized the rare family member disorazole C<sub>1</sub> (Fig. 1), which is devoid of reactive groups. It is remarkable that disorazole C<sub>1</sub> retained antimitotic activity (Wipf and Graham, 2004; Wipf et al., 2006). Structural analogs suggested that the functional group array of disorazole C<sub>1</sub> and its three-dimensional conformation were critical for biological activity, but little is known about its mechanism of action. In the current comprehensive report, we demonstrate that disorazole C<sub>1</sub> has potent antiproliferative activity against a wide variety of human tumor cells, disrupts cellular microtubule integrity, blocks tubulin polymerization in vitro, binds tubulin in a unique manner, and causes apoptosis and premature cellular senes-
cence, all attributes associated with a promising anticancer agent.

Materials and Methods

Cell Culture Reagents and Proliferation Assays. Cells were cultured in the following media supplemented with 10% fetal bovine serum (VWR, West Chester, PA): PtK2 rat kangaroo kidney epithelial cells in minimal essential medium-α; head and neck squamous cell carcinoma cell lines in Dulbecco’s modified Eagle’s medium; A549 and WI-38 fibroblasts in basal medium Eagle; UPCI:SCC103 in minimal essential medium; and MDA-MB-231, PC-3, and 2008 in RPMI; and HCT116 in McCoy’s 5A. Unless otherwise indicated, all media, sera, and supplements were obtained from Invitrogen (Carlsbad, CA), and other reagents were from Sigma-Aldrich (St. Louis, MO).

Inhibition of growth was determined spectrophotometrically with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or by an enzyme-linked immunosorbent assay (Promega, Madison, WI). Alternatively, in some studies, we plated cells twice to remove antibiotics and incubated for 24 h with compounds diluted in antibiotic-free growth medium. Cells were processed to visualize microtubules and DNA, and digital images were collected and manipulated as described previously (Stout et al., 2006). A549 cells were plated on coverslips in six-well plates for 24 h before compound treatment, fixed in 3.7% paraformaldehyde, and incubated in 0.1% Triton X-100 at 4°C for 7 min. A 1% solution of bovine serum albumin in phosphate-buffered saline plus 0.1% Tween was used as the blocking buffer. Microtubules were visualized using an anti-α-tubulin mouse monoclonal antibody (Abcam Inc., Cambridge, MA) with goat-anti-mouse Alexa Fluor488 (Invitrogen) secondary antibody diluted in 1% bovine serum albumin/phosphate-buffered saline plus 0.1% Tween. Nuclei were visualized with the fluorescent dye 4,6-diamidino-2-phenylindole and an Olympus BX60 epifluorescence microscope (Olympus, Tokyo, Japan). Images were taken using a Hamamatsu Argus-20 CCD camera and image processor (Hamamatsu Corporation, Bridgewater, NJ).

Radioligand Binding and Inhibition of Tubulin Assembly. Tubulin was isolated from bovine brain as described previously (Hamel and Lin, 1984). [3H]Vinblastine (specific activity, 61–315 mCi/mmol) and Sephadex G-50 were from GE Healthcare (Chalfont St. Giles, UK). Handee centrifuge columns and the bicinchoninic acid protein assay kit were from Pierce Chemical (Rockford, IL). [3H]Dolastatin 10 (specific activity, 26–133 mCi/mmol), dolastatin 10, and paclitaxel were from the Drug Synthesis and Chemistry Branch at the National Cancer Institute (Rockville, MD). Radiolabeled ligand binding to tubulin was measured by centrifugal gel filtration and scintillation spectrometry as described previously (Bai et al., 1995b), with minor modifications (Wang et al., 2007). The average stoichiometry of binding in the control reaction mixture was 0.63 mol [3H]vinblastine or [3H]dolastatin 10/mol of tubulin. For the tubulin assembly studies, we used homogenous bovine brain tubulin (10 μM) and previously described methods (Wang et al., 2007).

Apoptosis and Senescence Assays. A549 cell were analyzed for apoptosis using a commercially available fluorescence terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) method with fluorescence microscopy as described by the manufacturer (Roche In Situ Cell Death Kit; Roche Diagnostics, Indianapolis, IN). For senescence measurements, A549 cells (3.5 × 10⁵ cells/well) were plated 24 h before treatment with DMSO vehicle or test compounds for 1 to 7 days. For 7-day treatments, individual wells were split on day 3 or 4 to avoid the cultures reaching confluence. β-Galactosidase staining was performed as described previously (Dimri et al., 1995) and quantified both by visual counting by a naive observer or by acquiring images with the bright-field module on an ArrayScan VTI and using the Cellomics Compartmental Analysis V3 Bioapplication (Cellomics, Inc., Pittsburgh, PA) to define cells with positive β-galactosidase staining (mean of 20 acquired fields/well). For BrdU incorporation, A549 cells were pretreated in thymidine-free medium, incubated for 6 h with BrdU, and visualized using a cell proliferation kit (GE Healthcare). BrdU images were acquired (20 fields/well) with an ArrayScan VTI and analyzed using the Cellomics Compartmental Analysis V3 Bioapplication to determine the percentage of cells with fluorescence greater than the set threshold and to quantify BrdU-positive cells. For Western blotting, A549 cells were treated with

compounds for 7 days as stated above followed by cell harvesting in ice-cold lysis buffer (50 mM Tris, pH 7.6, containing 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100) supplemented with protease and phosphatase inhibitors. Protein concentrations in cell lysates were determined with the BCA protein assay kit (Promege). Individual proteins were detected by standard Western blotting methods with the following antibodies: p53, p85, phospho-Rb (Ser780), p21, and GAPDH antibodies (Cell Signaling Technology Inc., Danvers, MA); p21 antibody (EMD Biosciences, San Diego); vinculin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); cyclin D antibody (BD Biosciences, San Jose, CA). Disodermolide was obtained from Novartis (Basel, Switzerland), and disorazole A1 was from Æterna Zentaris GmbH (Frankfurt, Germany).

Results

Disorazole C1 is a Potent Inhibitor of Cell Proliferation, Interferes with Tubulin Polymerization, and Binds to Tubulin. As an extension of our previous study with HeLa cells (Wipf et al., 2006), we examined the growth-inhibitory activity of disorazole C1 using 11 other human tumor carcinoma cell lines (Table 1). Disorazole C1 was remarkably potent, with an average 50% growth-inhibitory concentration (IC50) of 1.7 ± 0.6 nM (S.E.M.). Head and neck cancer cell lines were particularly sensitive to disorazole C1, with an average IC50 value of 358 ± 56 pM. The p53 wild-type HCT116 cells exhibited similar sensitivity to disorazole C1 compared with the p53 null MDA-MB-231 cells. When quiescent WI-38 fibroblasts were exposed to disorazole C1 for 72 h, we observed no change in cell number or morphology. In contrast, proliferating WI-38 cells were sensitive to disorazole C1, indicating that active cell division was important for the cytotoxic effects of disorazole C1.

Disorazole A1 was reported previously to inhibit tubulin polymerization in vitro at substoichiometric concentrations and block cell proliferation at the G2/M phase (Elnakady et al., 2004). We previously observed that disorazole C1 caused G2/M phase arrest with HeLa cells (Wipf et al., 2006). As illustrated in Fig. 2A, disorazole C1 clearly disrupted GTP-mediated tubulin assembly in a concentration-dependent manner, with an IC50 of 11.8 ± 0.4 μM (Fig. 2A), indicating a compound/tubulin stoichiometry of approximately 1:1.

We next probed the ability of disorazole C1 to inhibit the binding of [3H]vinblastine or [3H]dolastatin 10 to purified tubulin as described previously (Bai et al., 1995b) (Fig. 2, B and C). As illustrated by the intersecting lines in the Hanes-Woolf plot (Fig. 2B), disorazole C1 inhibited [3H]vinblastine binding in an noncompetitive manner, with a K_i of 4.5 ± 0.6 μM. With this linear transformation, the lines would be parallel if the inhibition was competitive. Dolastatin 10 binds at the depsipeptide binding site on tubulin, which overlaps with the vinca alkaloid binding site (Bai et al., 1995a,b). It is interesting that we also found noncompetitive inhibition of [3H]dolastatin 10 binding by disorazole C1, with a K_i of 10.6 ± 1.5 μM, suggesting that disorazole C1 might bind tubulin uniquely among known antimitotic agents.

We next treated A549 cells with IC50 concentrations of disorazole C1 or vinblastine and visualized microtubule integrity by immunofluorescence microscopy (Fig. 3). Compared with vehicle control, disorazole C1 disrupted microtubules as early as 24 h (Fig. 3b) with complete disruption within 72 h (Fig. 3c). Even within 1 h, disorazole C1 (2 nM, Fig. 3f; 10 nM, Fig. 3g; 20 nM, Fig. 3h) and 20 nM vinblastine (Fig. 3i) caused a dissolution of microtubules.

To further assess the effects of disorazole C1 on microtubules at interphase and mitosis, we examined PtK2 rat kangaroo kidney epithelial cells, which are widely used to study antimitotics because they have a flat morphology and large chromosomes, allowing greater visualization. PtK2 cells were treated for 24 h in the presence of disorazole C1 (5, 25, or 100 nM) or the inactive but structurally closely related analog O1OA (Fig. 1). O1OA had no effect on microtubules at interphase or mitosis, where chromosomes aligned normally along the metaphase plate (Fig. 4). In contrast, disorazole C1 completely disrupted microtubules at both concentrations. At mitosis, complete misalignment of chromosomes was evident, as were multipolar spindles and dispersed chromosomes with no attached microtubules. These results, in combination with the data described in Fig. 3, confirmed that disorazole C1 treatment had a dramatic effect on cellular microtubules, causing disruption of normal mitotic processes.

We next determined the durability of the growth-inhibitory effects of disorazole C1. A549 cells were treated for 1 h with 10 nM disorazole C1, 1 μM nocodazole, or DMSO vehicle and

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>IC50 ± S.E.M.*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Disorazole C1</td>
</tr>
<tr>
<td>A549</td>
<td>2.21 ± 0.23</td>
</tr>
<tr>
<td>PC-3</td>
<td>1.57 ± 0.10</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>3.53 ± 0.19</td>
</tr>
<tr>
<td>2008</td>
<td>1.91 ± 0.23</td>
</tr>
<tr>
<td>HCT116</td>
<td>1.09 ± 0.41</td>
</tr>
<tr>
<td>UPCI:15CC104</td>
<td>0.67 ± 0.54</td>
</tr>
<tr>
<td>PCI 15A</td>
<td>0.26 ± 0.03</td>
</tr>
<tr>
<td>PCI 15B</td>
<td>0.34 ± 0.03</td>
</tr>
<tr>
<td>PCI 37A</td>
<td>0.53 ± 0.07</td>
</tr>
<tr>
<td>PCI 37B</td>
<td>0.26 ± 0.02</td>
</tr>
<tr>
<td>UMSSC22A</td>
<td>0.40 ± 0.06</td>
</tr>
<tr>
<td>WI-38 confluent</td>
<td>1.74 ± 0.78</td>
</tr>
</tbody>
</table>

* IC50 values are mean of eight determinations.
were maintained in medium containing compound (contin) or washed and maintained in medium lacking compound (wash) and incubated for 1 to 144 h (Fig. 5A). The cytotoxic effects of nocodazole, a reversible inhibitor of mitosis, were completely reversed with compound washout. In contrast, cell viability continued to decline during the 72 h in cultures exposed briefly (1 h) or continuously to 10 nM disorazole C1. The number of surviving cell remained relatively constant between 72 and 144 h, suggesting growth arrest and possible senescence. A microscopic analysis of microtubule integrity

Fig. 2. Disorazole C1 disrupts microtubule assembly and binds to tubulin in vitro. A, bovine brain tubulin was preincubated with disorazole C1 or vehicle and monosodium glutamate for 15 min at 30°C. The reaction mixture was cooled to 0°C, GTP was added, reaction mixtures were transferred to cuvettes, held at 2.5°C in a spectrophotometer, and absorbance (turbidity) was read at 350 nm. After a baseline was established, the temperature was raised to 30°C (~1 min). After 20 min, the temperature was returned to 2.5°C. GTP alone (no test compound) was assigned as 100% assembly (positive control) and DMSO alone (no test compound, no GTP) as 0% assembly (negative control). Hanes-Woolf plot of disorazole C1 inhibition of 3Hvinblastine (B) or 3Hdolastatin 10 (C) binding to 10 μM bovine brain tubulin. The mixtures were incubated for 30 min at room temperature and bound versus free radiolabeled ligand was separated using Sephadex G-50 columns. The amount of radiolabeled ligand bound to tubulin was determined using scintillation spectrometry. The substrate concentration ([S]) is indicated on the abscissa and the ratio of the substrate concentration to the reaction velocity ([v]) indicated on the ordinate.

Fig. 3. Disorazole C1 disrupts microtubules in vivo. Microtubules in A549 cells were partially disrupted after disorazole treatment at 2 nM for 24 h (b) and more completely at 72 h (c) compared with DMSO vehicle control (a). The disruption was similar to that seen with 2 nM vinblastine treatment at 24 h (d) and 72 h (e). A concentration response effect on microtubules after a 1-h treatment was observed with 2 nM (f), 10 nM (g), and 20 nM (h) disorazole C1, similar to 20 nM vinblastine (i). With both compounds, apparent tubulin aggregation was observed at higher concentrations (h and i). Cells were fixed and stained with anti-α-tubulin antibody to visualize microtubules (green) and 4,6-diamidino-2-phenylindole to visualize nuclei (blue).

Fig. 4. Disorazole C1 disrupts microtubules at interphase and metaphase. Mammalian PtK2 cells were treated with the indicated concentrations of either O1OA (inactive analog of disorazole C1) or disorazole C1 for 24 h at 37°C. Cells were fixed and stained with anti-α-tubulin antibody to visualize microtubules (red) and Hoechst 33342 to visualize chromosomes (blue). All images were collected with a Nikon E600 microscope (Nikon, Tokyo, Japan) equipped with a Roper CoolSnap HQ digital camera (Roper Scientific, Trenton, NJ) at 40× (interphase) or 100× (mitotic spindles) objectives. Top, interphase; bottom, mitosis. Bars, 10 μm.
also suggested the disorazole C1-mediated microtubule disruption was not readily reversible. Furthermore, the IC₅₀ values for cells treated for 1 h or 7 days were similar (2.2 versus 1.5 nM). These growth-inhibitory results were consistent with a previous report using disorazole A₁, in which the cytotoxic effects were prolonged (Elnakady et al., 2004). Disorazole C₁ at 10 nM caused some apoptosis in A549 cells (Fig. 5B), although it was much less effective than what has been reported for disorazole A₁ (Elnakady et al., 2004). Thus, treatment of A549 cells with 2 nM disorazole C₁ for 24 or 48 h caused no significant apoptosis as detected by a TUNEL assay, although treatment with 10 nM for 48 h did cause detectable apoptosis (Fig. 5B). These results indicate that the highly reactive vinyl oxirane subunit in disorazole A₁ was dispensable for the prolonged cytotoxicity caused by the disorazole family members.

**Disorazole C₁ Induces Premature Senescence.** Because drug-resistant cells have been so valuable in understanding the mechanism of action of new small molecules, we attempted to generate A549 cells that were resistant to disorazole C₁ using chronic exposure to increasing compound concentrations in culture. Although our initial efforts were unsuccessful, when we examined the population that survived a 1-week exposure, we observed cells with an enlarged, flattened morphology. These cells ceased to divide but remained viable for >50 days in the presence or absence of disorazole C₁. We tested whether or not these cells entered premature senescence using a classic β-galactosidase staining procedure at pH 6.0 after treatment of A549 cells for 7 days with 1 to 10 nM disorazole C₁ (Fig. 6). Cells treated with DMSO or the inactive O1OA analog displayed only a few sparse β-galactosidase-positive cells, whereas the positive control, doxorubicin, showed abundant β-galactosidase staining at the IC₅₀ concentration of 50 nM. Cells treated with an IC₅₀ concentration of discodermolide also displayed high levels of β-galactosidase-positive cells, whereas an equipotent growth-inhibitory concentration of vinblastine had no effect consistent with previous results (Chang et al., 1999; Klein et al., 2005). Disorazole C₁ treatment resulted in positive β-galactosidase staining even at concentrations below the growth IC₅₀ (1 nM). The percentage of β-galactosidase-positive cells with disorazole C₁ treatment was comparable with that seen with doxorubicin. Disorazole C₁ also produced positive β-galactosidase human colon cancer (HCT116), lung cancer (H1299), and oral squamous carcinoma (UPCI:SCC103) cells, but not PC-3 prostate cancer cells (data not shown).
Alterations in the protein expression profiles of some of the classic markers of premature senescence also supported the hypothesis that these metabolically active, nondividing cells had undergone premature senescence. A549 and HCT116 cells were treated for 7 days with concentrations of 50 nM doxorubicin, 2 nM disorazole C1, 25 nM discodermolide, or 2 nM vinblastine that had equivalent growth inhibition. Cells were lysed, protein was isolated, and the protein expression was determined by Western blotting (Fig. 6B). All compounds increased the levels of cyclin dependent kinase inhibitor p21 and cyclin D. Lower levels of Ser780 phosphorylated pRb and total pRb levels were also observed as expected for cells undergoing cell cycle arrest and premature senescence. Vinblastine (2 nM) also induced p53, p21, Rb, and cyclin D consistent with cell cycle arrest and senescence, although little β-galactosidase staining was observed (Figs. 6 and 7).

Further documenting the role of microtubule disruption in premature senescence, we observed DNA synthesis as measured by BrdU incorporation was inhibited by 67% in A549 cells treated for 1 day with IC50 concentration of disorazole C1 (2 nM), which was equivalent to that seen with the 50% growth-inhibitory concentration of doxorubicin (50 nM) (Supplemental Fig. 1; Supplemental Table 1). In contrast, almost all cells incorporated BrdU after treatment with the inactive analog O1OA, vinblastine, discodermolide, or DMSO vehicle control, indicating actively dividing cells. By 7 days, almost no cells were actively dividing after treatment with doxorubicin, discodermolide, or disorazole C1 (≥0.5 nM) (Supplemental Fig. 1; Supplemental Table 1). Some decrease in BrdU-positive cells was seen after a week of treatment with either 10 nM O1OA or 2 nM vinblastine. We also excluded the possibility that the induction of premature senescence was the product of double-strand DNA breaks because we did not detect an increase in Ser139 phosphorylation of γH2AX after treatment with either disorazole C1 or vinblastine (Supplemental Fig. 2). These results, in combination with the positive β-galactosidase staining and changes in cell cycle protein markers, indicate that disorazole C1 could induce premature senescence in some human tumor cells.

**Fig. 7.** Disorazole C1 causes premature senescence. A549 cells were treated for 7 days with vehicle (DMSO), doxorubicin (DOX; 50 nM), the inactive analog O1OA (10 nM), discodermolide (DISCO; 25 nM) vinblastine (VBL; 2 nM), or disorazole C1 (C1, 1–10 nM) followed by β-galactosidase staining.

### Discussion

The highly electrophilic divinyl oxirane moiety of disorazole A1 has been an attractive candidate mediator for the inhibition of tubulin polymerization, and our results indicate that at least some of the pharmacological activity of the disorazole family resides in other aspect of the disorazole pharmacophore. The disorazole C1 concentration required to inhibit tubulin polymerization by 50% in vitro (namely, 11.8 μM) was approximately an order of magnitude higher than the IC50 values reported for disorazole A1 (1.8 μM) using a similar assay (Elnakady et al., 2004). Our in vitro tubulin binding studies indicated that disorazole C1 had a unique direct tubulin binding interaction, possibly binding at or near a site typically occupied by vinblastine and dolastatin 10. However, we could not rule out the possibility that disorazole C1 bound to a completely unrelated site on tubulin, instigating a conformational change that allosterically interferes with vinblastine and dolastatin 10 binding. Further studies are needed to determine the exact binding domain of disorazole C1 on tubulin. These results indicate disorazole C1, like disorazole A1 (Elnakady et al., 2004), inhibited tubulin polymerization in the absence of abundant microtubule-associated proteins.

Disorazole C1 prevented proper assembly of microtubules within cells. The disorazole C1 concentration required to inhibit tubulin polymerization by 50% in vitro would be expected to be higher because the concentration of purified tubulin (10 μM) used in the in vitro reactions was intentionally high to permit robust detection. Moreover, it is now recognized that most effective anticancer drugs affect microtubule depolymerization or polymerization at much lower concentrations than required for in vitro studies (Jordan and Wilson, 2004). The lower concentration of disorazole C1 or A1 required to disrupt cellular proliferation probably reflected the need to affect only a small fraction of the tubulin/microtubule dynamics to block the cell division machinery. The breakdown of microtubules was seen as early as 15 min after a 5 nM disorazole C1 treatment, with complete absence of cells with visible microtubules within 4 h (data not shown).

We speculate that the long-lived disorazole C1 cytotoxicity might be because of misalignment of chromosomes at the metaphase plate, consistent with the G2/M arrest and increase in mitotic index that we described previously (Wipf et al., 2006). All of these data indicated that disorazole C1 was a potent, cytotoxic, microtubule destabilizer that prevents normal cell division. Nonetheless, the previously reported IC50 values for growth inhibition with disorazole A1 suggest that it is even more potent than disorazole C1, probably because of the highly reactive divinyl oxirane moiety. In preliminary growth inhibition studies with HeLa cells, we observed an IC50 of 47 pM for disorazole A1 compared with an IC50 of 219 pM for disorazole C1. It remains to be determined whether disorazole C1 has a better therapeutic potential compared with the more potent disorazole A1.

Proliferating cells that are subjected to significant harmful stress rapidly exit the cell cycle through several concurrent failsafe “checkpoint” mechanisms enabling DNA repair and suppressing possible tumorigenesis. If these cell cycle checkpoints are deficient because of the presence of mutations or overwhelming damage, cells generally engage in apoptosis or senescence. Senescence is defined as permanent cell-cycle...
arrest preventing proliferation but permitting metabolic activity. Senescent cells have an enlarged, flattened morphology with an increased cytoplasmic area, increased granularity, extensive cytoplasmic vacuoles, and multinucleation (Schmitt, 2007). There currently is no single accepted biochemical defining marker for the senescence phenotype, although perinuclear lysosomal presence of β-galactosidase is often considered to be a senescence characteristic (Dimri et al., 1995). In addition, senescent cells do not synthesize DNA and therefore display decreased BrdU uptake. Cells undergoing senescence show changes in the expression of genes involved in tumor suppression, cell cycle progression, mitosis, and DNA replication. Thus, the tumor suppressor protein p53, which up-regulates the cyclin-dependent kinase inhibitors p21 and p16, is activated and promotes growth arrest in cells undergoing senescence (Stein et al., 1999; Roninson, 2003; Serrano, 2007). The proliferation blockage associated with senescence seems to be irreversible because few cells actually recover from prolonged up-regulation of tumor suppressors, such as p53, p21, and p16.

Chemotherapy-induced senescence has been reported with mechanistically distinct agents including DNA alkylators, antimetabolites, topoisomerase inhibitors, irradiation, and some microtubule stabilizers (Chang et al., 1999; Klein et al., 2005; Schmitt, 2007). Senescence is typically induced at low drug concentrations, whereas high concentrations produce overwhelming damage that favors apoptosis. For example, treatment of human hepatoma cells with a low concentration of the indirect DNA-damaging agent doxorubicin (<100 nM) induces senescence, eventually leading to mitotic catastrophe, whereas a high concentration (20 μM) leads to apoptosis (Eom et al., 2005). Considering the broad mechanisms of action of the anticancer agents causally involved in tumor cell senescence, it is surprising that in initial studies, clinically important inhibitors of tubulin polymerization, such as vinblastine and vincristine, were not observed to be potent inducers of senescence (Chang et al., 1999; Schmitt, 2007), even though one would hypothesize that kinetochore nonattachment recognized by mitotic spindle checkpoints might lead to senescence (Yamada and Gorbsky, 2006). It is interesting that recent work by Arthur et al. (2007) suggests that the inhibitor of tubulin polymerization, JG-03-14 (Arthur et al., 2007), caused senescence in residual surviving cell populations. Treatment of L929 mouse fibroblasts and PtK2 rat kangaroo kidney epithelial cells for 5 days with disorazole A1 caused enlarged cells with increased metabolic activity that ceased to divide, possibly indicating that these surviving cells adopted a senescence phenotype (Elnakady et al., 2004). We found positive β-galactosidase staining in cells treated with disorazole C1 at concentrations well below the IC50. Prominent β-galactosidase staining was not observed previously with vinblatine (Lee et al., 2006), which no doubt contributed to the current belief that inhibition of microtubule polymerization does not provide a signal for senescence (Schmitt, 2007). We also did not observe significant β-galactosidase expression in cells treated with vinblatine or vincristine at their IC50 concentrations for growth inhibition. It is also important to note, however, that β-galactosidase expression has been questioned as a marker for senescence (Lee et al., 2006). Thus, we examined additional markers, including increased p53 and p21 with down-regulation in total Rb and phospho-Rb consistent with senescence. A549 cells do not express another common marker of senescence, p16INK4A, rather, they use p21 to maintain cell cycle arrest and senescence (Kashiwabara et al., 1998; McConnell et al., 1998). We saw increases in the levels of cyclin D, and the cyclin-dependent kinase inhibitor p21 was also elevated. It has been suggested that this phenomenon occurs because of hypermitotic senescence, where supraphysiologic levels of mitogens (Ras/Raf/mitogen-activated protein kinase) increase cyclin D levels (Blagosklonny, 2003), but to date, our efforts to identify activation of the mitogen-activated protein kinase pathway have not been successful. Finally, another marker of senescence is inhibition of DNA synthesis, which was markedly decreased in cells exposed to disorazole C1 as early as 24 h after treatment with low concentrations (≈0.5 nM); both discodermolide and vinblastine were less efficacious.

In summary, our data provide evidence that microtubule destabilization can suppress cancer cell growth by inducing premature senescence at concentrations at or below the IC50 for growth inhibition. Other microtubule-destabilizing agents, namely JG-03-14, also are reported to cause premature senescence (Arthur et al., 2007), albeit at higher concentrations (namely 500 nM, which causes 70–80% growth inhibition) than that required with disorazole C1. These results illustrate that microtubule disruption, like some other forms of cellular stress, provided intracellular signals promoting premature senescence, at least in some tumor cell types. The propensity of disorazole C1 to promote senescence may be related to the prolonged cellular effects or the nature of its interactions with microtubules. The symmetric synthesis of disorazole C1 (Wipf and Graham, 2004; Wipf et al., 2006) enables the production of radiolabeled compound and analog development. We speculate that disorazole C1 could be a potent and valuable chemical probe for studying the process of premature senescence induced by mitotic spindle disruption.

Acknowledgments

We thank Drs. Jennifer Grandis (University of Pittsburgh) and June Biedler (Memorial Sloan-Kettering Cancer Center, New York, NY) for providing the head and neck carcinoma and Chinese hamster lung cell lines, respectively; Drs. Kenneth Bair and Fred Kinder at Novartis for providing the discodermolide; and Dr. Eckhard Günther at Äterna Zentaris for providing disorazole A1.

References


Tierno MB, Petrik B, Nickischer D, and Johnston P Application Note LC01612000, Thermo Scientific.


**Address correspondence to:** John S. Lazo, Department of Pharmacology and Chemical Biology, University of Pittsburgh Drug Discovery Institute, Biomedical Science Tower 3, Suite 10040, 3401 Fifth Avenue, University of Pittsburgh, Pittsburgh, PA 15260. E-mail: lazo@pitt.edu
Supplemental Figure 2